Fathom Therapeutics Secures Funding Round Led by Chemistry, Alexandria Venture Investments, and NY Ventures from Empire State Development, Among Others
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 27 2026
0mins
Should l Buy FTHM?
Source: moomoo
- Funding Sources: The funding for Fathom Therapeutics is led by Chemistry, Alexandria Venture Investments, and Empire State Development's NY Ventures.
- Investment Focus: The investments are aimed at advancing therapeutic innovations in the healthcare sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FTHM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FTHM
Wall Street analysts forecast FTHM stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.818
Low
2.50
Averages
2.50
High
2.50
Current: 0.818
Low
2.50
Averages
2.50
High
2.50
About FTHM
Fathom Holdings Inc. is a national, technology-driven real estate services platform that integrates residential brokerage, mortgage, title, and SaaS offerings through its proprietary cloud-based software, intelliAgent. The Company's brands include Fathom Realty, Encompass Lending, intelliAgent, Real Results, and Verus Title. The Company's segments include Real Estate Brokerage, Mortgage and Technology. Its Real Estate Brokerage segment provides real estate brokerage services. The Company operates as a real estate brokerage company, working with real estate agents to help individuals purchase and sell residential and commercial properties, primarily in the South, Atlantic, Southwest, and Western parts of the United States. Its Mortgage segment provides residential loan origination and underwriting services. Its Technology segment provides SaaS solutions and data mining for third party customers and continues to develop its intelliAgent platform for use by its real estate agents.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FATHOM RECEIVES STRATEGIC FUNDING FROM CVS HEALTH VENTURES TO BOOST ENTERPRISE-WIDE AUTONOMOUS CODING INITIATIVES
- Investment Announcement: Fathom has secured a strategic investment from CVS Health Ventures.
- Focus on Innovation: The funding aims to accelerate enterprise-wide autonomous coding solutions.
See More
Fathom Therapeutics Secures Funding Round Led by Chemistry, Alexandria Venture Investments, and NY Ventures from Empire State Development, Among Others
- Funding Sources: The funding for Fathom Therapeutics is led by Chemistry, Alexandria Venture Investments, and Empire State Development's NY Ventures.
- Investment Focus: The investments are aimed at advancing therapeutic innovations in the healthcare sector.
See More
Fathom Therapeutics, previously known as AtomMap, Secures $47 Million in Oversubscribed Series A Funding to Advance Physics and AI-Driven Small Molecule Development for Next-Gen Medicines
Funding Announcement: Fathom Therapeutics, formerly known as Atommap, has successfully raised $47 million in a recent funding round.
Research Focus: The funds will be utilized to advance their research in translating physics and AI-enabled small molecule design into next-generation medicines.
See More
Fathom Holdings Reports 25% Revenue Growth in 2025
- Annual Revenue Growth: Fathom Holdings achieved $420 million in total revenue for 2025, marking a 25% year-over-year increase, which underscores the company's robust performance despite industry challenges.
- Gross Profit Increase: The gross profit for 2025 reached $34.2 million, up 20.8% year-over-year, primarily driven by the acquisition of My Home Group and strong agent recruitment, enhancing the company's profitability.
- Mortgage Business Surge: In Q4 2025, mortgage revenue surged by 70% year-over-year to $3.4 million, indicating significant progress in expanding ancillary businesses and improving the overall revenue mix.
- Brokerage Revenue Decline: Despite overall revenue growth, Fathom experienced a 3.2% decline in brokerage revenue in Q4 2025, leading to an increase in GAAP net loss to $6.7 million, reflecting ongoing challenges in the market environment.
See More
Fathom Holdings Inc. Reports Q4 2025 Earnings with Strategic Growth Insights
- Significant Revenue Growth: Fathom Holdings reported $420 million in revenue for FY 2025, reflecting a 25% year-over-year increase, and a nearly 15% rise in total transactions, demonstrating the company's resilience and adaptability in a challenging housing market.
- New Commission Structure Implementation: The launch of the Edge program transitions commission fees from annual to monthly, introducing a 7% split and a $250 transaction fee, aimed at significantly enhancing gross profit before any market recovery.
- High-Margin Program Expansion: The CEO projects that Elevate and START will account for at least 10% of total transaction volume by year-end, with plans to increase this to over 15% by the end of 2027, which will drive higher profit margins and support long-term growth.
- Improved Financial Performance: Despite a net loss of $6.7 million in Q4, gross profit margin increased to 8.1% from 7.2% year-over-year, indicating positive progress in cost management and profitability enhancement efforts.
See More
Fathom Holdings Q4 Earnings Miss Expectations
- Disappointing Earnings: Fathom Holdings reported a Q4 GAAP EPS of -$0.21, missing expectations by $0.07, indicating pressure on the company's profitability which may affect investor confidence.
- Revenue Decline: The company posted revenues of $90.6 million, a 1.2% year-over-year decrease, falling short of the expected $96.95 million, reflecting challenges from weak market demand and increased competition.
- Market Reaction: Following the earnings miss, Fathom Holdings' stock price may face downward pressure, prompting investors to closely monitor subsequent market dynamics and the company's strategic responses.
- Uncertain Future Outlook: Given the current economic environment, Fathom Holdings' profitability and revenue growth prospects appear uncertain, potentially leading investors to reassess the long-term investment value of the company.
See More
FATHOM RECEIVES STRATEGIC FUNDING FROM CVS HEALTH VENTURES TO BOOST ENTERPRISE-WIDE AUTONOMOUS CODING INITIATIVES
- Investment Announcement: Fathom has secured a strategic investment from CVS Health Ventures.
- Focus on Innovation: The funding aims to accelerate enterprise-wide autonomous coding solutions.
See More
Fathom Therapeutics Secures Funding Round Led by Chemistry, Alexandria Venture Investments, and NY Ventures from Empire State Development, Among Others
- Funding Sources: The funding for Fathom Therapeutics is led by Chemistry, Alexandria Venture Investments, and Empire State Development's NY Ventures.
- Investment Focus: The investments are aimed at advancing therapeutic innovations in the healthcare sector.
See More
Fathom Therapeutics, previously known as AtomMap, Secures $47 Million in Oversubscribed Series A Funding to Advance Physics and AI-Driven Small Molecule Development for Next-Gen Medicines
Funding Announcement: Fathom Therapeutics, formerly known as Atommap, has successfully raised $47 million in a recent funding round.
Research Focus: The funds will be utilized to advance their research in translating physics and AI-enabled small molecule design into next-generation medicines.
See More
Fathom Holdings Reports 25% Revenue Growth in 2025
- Annual Revenue Growth: Fathom Holdings achieved $420 million in total revenue for 2025, marking a 25% year-over-year increase, which underscores the company's robust performance despite industry challenges.
- Gross Profit Increase: The gross profit for 2025 reached $34.2 million, up 20.8% year-over-year, primarily driven by the acquisition of My Home Group and strong agent recruitment, enhancing the company's profitability.
- Mortgage Business Surge: In Q4 2025, mortgage revenue surged by 70% year-over-year to $3.4 million, indicating significant progress in expanding ancillary businesses and improving the overall revenue mix.
- Brokerage Revenue Decline: Despite overall revenue growth, Fathom experienced a 3.2% decline in brokerage revenue in Q4 2025, leading to an increase in GAAP net loss to $6.7 million, reflecting ongoing challenges in the market environment.
See More
Fathom Holdings Inc. Reports Q4 2025 Earnings with Strategic Growth Insights
- Significant Revenue Growth: Fathom Holdings reported $420 million in revenue for FY 2025, reflecting a 25% year-over-year increase, and a nearly 15% rise in total transactions, demonstrating the company's resilience and adaptability in a challenging housing market.
- New Commission Structure Implementation: The launch of the Edge program transitions commission fees from annual to monthly, introducing a 7% split and a $250 transaction fee, aimed at significantly enhancing gross profit before any market recovery.
- High-Margin Program Expansion: The CEO projects that Elevate and START will account for at least 10% of total transaction volume by year-end, with plans to increase this to over 15% by the end of 2027, which will drive higher profit margins and support long-term growth.
- Improved Financial Performance: Despite a net loss of $6.7 million in Q4, gross profit margin increased to 8.1% from 7.2% year-over-year, indicating positive progress in cost management and profitability enhancement efforts.
See More
Fathom Holdings Q4 Earnings Miss Expectations
- Disappointing Earnings: Fathom Holdings reported a Q4 GAAP EPS of -$0.21, missing expectations by $0.07, indicating pressure on the company's profitability which may affect investor confidence.
- Revenue Decline: The company posted revenues of $90.6 million, a 1.2% year-over-year decrease, falling short of the expected $96.95 million, reflecting challenges from weak market demand and increased competition.
- Market Reaction: Following the earnings miss, Fathom Holdings' stock price may face downward pressure, prompting investors to closely monitor subsequent market dynamics and the company's strategic responses.
- Uncertain Future Outlook: Given the current economic environment, Fathom Holdings' profitability and revenue growth prospects appear uncertain, potentially leading investors to reassess the long-term investment value of the company.
See More
